OOIR: Observatory of International Research

Papers

(The H4-Index of Liver International is 37. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
Helicobacter pylori‐Associated Surrogate Markers of Intestinal Permeability, Bacterial Translocation and Gut Barrier Damage in Liver Cirrhosis	141
Is HCV elimination among persons living with HIV feasible? Data from the NoCo study in the setting of the ICONA cohort	116
TIPS Superiority in Refractory Variceal Haemorrhage: Insights From the TIPSEMS ‐ VB	94
Response to Letter to the Editor: “Chronic Nanoplastic Exposure as a Novel Risk Amplifier for MASLD Progression”	92
Navigating portal hypertension: Unlocking safe passage to healthy pregnancy in EHPVO	91
Importance of gender differences in body composition for liver transplantation and the ‘Sarco‐Model’ study	89
Golexanolone improves fatigue, motor incoordination and gait and memory in rats with bile duct ligation	85
Cardiac Geometry in Cirrhosis: Translation to Public Health and Trial Design	84
Immunogenicity and safety of a third dose of anti‐SARS‐CoV‐2 BNT16b2 vaccine in liver transplant recipients	79
Alcohol‐related hepatocellular carcinoma is a heterogenous condition: Lessons from a latent class analysis	73
Reply to “Probiotics for Hepatic Encephalopathy Prevention After TIPS : Still an Open Question”	69
Benefits of Using cT1 for Risk Stratification in MASLD	68
Systemic inflammation is linked to liver fibrogenesis in patients with advanced chronic liver disease	60
HBV cure—The light at the end of the tunnel?	58
Fatty liver disease at the basis of cardiac remodelling and increased heart rate: Insights from the UK Biobank	56
Inside Front Cover	55
Is ageing a problematic hurdle to the efficacy of first‐line atezolizumab plus bevacizumab in hepatocellular carcinoma?	52
Letter to the Editor regarding “Long‐term exposure to air pollution and incident non‐alcoholic fatty liver disease and cirrhosis”	52
Changing epidemiological features of hepatocellular carcinoma: Taiwan's position	48
Different methodologies of protein induced by vitamin K absence or antagonist II in patients without hepatocellular carcinoma	47
Is fresh frozen plasma transfusion associated with outcomes in acute variceal bleeding?	47
Interpreting elevated liver blood test results through a genetic lens: A genome‐wide association study	47
Bringing evidence to the MAFLD‐MASLD debate	46
Five‐year outcomes in liver transplant patients receiving everolimus with or without a calcineurin inhibitor: Results from the CERTITUDE study	44
Association of Liver Disease and Chronic Pruritus: A Case–Control Study	42

Clarifying Treatment Pathway Differences and Exposure Bias in the CHIEF Cohort Study	41
Liver Disease Complicating Familial Mediterranean Fever: A Study on 66 Patients Out of 533 Adult From the JIR Cohort	41
The Relationship Between TNF‐α Inhibitor Potency and HBV Reactivation in Patients With Rheumatic Disorders	40
Determinants of worse liver‐related outcome according to HDV infection among HBsAg positive persons living with HIV: Data from the ICONA cohort	40
On Evaluating GPT ‐4 for CHB Treatment Recommendations: Reproducibility, Vignette Design and Promp	40
Time since liver transplant and immunosuppression withdrawal outcomes: Systematic review and individual patient data meta‐analysis	39
Reassessing the Use of Nivolumab Plus Ipilimumab After Atezolizumab Plus Bevacizumab in Advanced HCC	38
Impact of socio‐economic environment on incidence of primary liver cancer in France between 2006 and 2016	38
Assessing Treatment Heterogeneity in Predictive Models for HCC Retreatment Response	38
RETRACTION : Interferons α, β, γ Each Inhibit Hepatitis C Virus Replication at the Level of Inte	38
Reply to Reconsidering the Impacts of Steatotic Liver Disease on Adverse Pregnancy Outcomes	38
Methylprednisolone‐Induced Liver Injury: Insights From FAERS Analysis and Comparison With DILIN Fi	37
Metformin synergistically enhances the antitumour activity of Lenvatinib in hepatocellular carcinoma by altering AKT‐FOXO3 signalling pathway	37